HTTP 200 verified twice
Finding your next stop…
Loading the latest directory information.
Loading the latest directory information.
Start here for the decision-making essentials: what Foundation Medicine does, who it is for, how it is accessed, and the first-party sources behind this profile.
US self-pay rates: FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne Heme $3,500
Foundation Medicine is a Boston-based global precision medicine company delivering AI-powered genomic diagnostic solutions for cancer. Its FDA-approved FoundationOne CDx and Liquid CDx tests provide comprehensive genomic profiling across 300+ genes, available to patients in 45+ countries with 100+ companion diagnostic indications.
Read-only public captures of Foundation Medicine’s homepage and verified pricing page. Screenshots are dated, never live embeds, and open full-screen.
Short answers to the questions buyers and builders commonly ask about Foundation Medicine. Each answer cites the shared ledger below, where every source is listed once.
AI-powered diagnostic tools leveraging precision medicine knowledge and real world data · NGS-based detection of base substitutions, insertions/deletions, copy number alterations, · FoundationOne®CDx is an FDA-approved qualitative next-generation sequencing based in vitro · FoundationOne®Liquid CDx is an FDA-approved qualitative next-generation sequencing based i
We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools
Tests must be ordered by a licensed healthcare provider · Biopharma companies worldwide seeking support across the therapy development lifecycle, fr · Solutions serve healthcare providers and biopharma partners
Ordering a Foundation Medicine test is simple and must be done by a licensed provider.
Transforming care throughout a patient's experience, from defining a diagnosis to determin · Comprehensive genomic profiling to guide therapy selection and clinical trial matching in · Comprehensive genomic profiling (CGP) to define diagnosis, determine appropriate treatment · IHC tests can be bundled by tumor type with a pathologist-led ordering option
We provide tests and solutions to transform care throughout a patient's experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring.
FoundationOne Heme and FoundationOne RNA are laboratory developed tests (LDTs) not cleared · Use of FoundationOne CDx/Liquid CDx does not guarantee a patient will be matched to a trea
FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration.
US self-pay rates: FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne Heme $3,500;
FoundationOne®CDx, FoundationOne®Liquid CDx, FoundationOne®Heme: $3,500
EMR integration with Epic, OncoEMR and other systems for ordering tests and receiving resu · FoundationOne CDx has national coverage for qualifying Medicare and Medicare Advantage pat
your EMR system (Epic, OncoEMR, etc.)
This profile connects the jobs Foundation Medicine is described as handling with its delivery model, access options and the subjects used to match it to related products in this directory.
Each fact points to a recorded source, making it easy to distinguish verified product information from claims that need checking.
HTTP 200 verified twice
Transformative Diagnostic Solutions in Cancer and Other Diseases
Headquartered in Boston as a global, patient-focused precision medicine company · AI-powered tools leveraging precision medicine knowledge and real-world data · Tests available to patients in 45+ countries globally
Foundation Medicine, Inc.
Delivering high-quality, transformative diagnostic solutions in cancer and other diseases
AI-powered diagnostic tools leveraging precision medicine knowledge and real world data
Transforming care throughout a patient's experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring
Cancer and disease diagnostic solutions
Genomic testing for cancer (comprehensive genomic profiling, CGP)
FlexOMx Lab, FoundationAccess, FoundationCore, FoundationInsights, FoundationOne, FoundationPlanner, FoundationReach, and Trial Boost
Boston
Global
A concise view of the jobs, capabilities and integrations described in the recorded product sources.
Documented product formats, platforms and official distribution destinations. Availability can vary by region and plan.
A concise history of software releases and material product changes. Events appear only when a dated source supports what changed.
This profile is being checked for dated releases and material product changes. Nothing appears here until the exact date and event can be verified from a recorded source.
Facts, answers, structured details, milestones and primary resource links cite this shared ledger. Each external page appears once; release tags from the same GitHub project are grouped under one release history.
These tools share a workflow, capability or audience with Foundation Medicine. They may complement it rather than replace it, and are not presented as integrations or endorsements.
Incorporated company (Inc.)
Quality First initiative to drive awareness about the importance of high-quality biomarker testing in cancer care
LinkedIn, X, YouTube, Facebook, Instagram and BlueSky
Global patient-focused precision medicine company delivering diagnostic solutions in cancer and other diseases
Comprehensive genomic profiling to guide therapy selection and clinical trial matching in advanced cancer
NGS-based detection of base substitutions, insertions/deletions, copy number alterations, and rearrangements/fusions across 300+ cancer-related genes
Tests available to patients in 45+ countries globally
Genomic diagnostic tests including FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne Heme, FoundationOne RNA, FoundationOne MRD, IHC, Germline, and PGx testing
Tests must be ordered by a licensed healthcare provider
EMR integration with Epic, OncoEMR and other systems for ordering tests and receiving results
Foundation Medicine online portal for placing orders and accessing patient results
FoundationOne CDx and FoundationOne Liquid CDx are FDA-approved in vitro diagnostic companion diagnostic tests
FoundationOne Heme and FoundationOne RNA are laboratory developed tests (LDTs) not cleared or approved by the FDA
FoundationAccess financial assistance program; 86% of patients have $0 financial responsibility for testing
US self-pay rates: FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne Heme $3,500; FoundationOne RNA $2,919.60; IHC $125 per test; Microdissection $205
Foundation Medicine, Inc. is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases.
Boston
Comprehensive genomic profiling (CGP) to define diagnosis, determine appropriate treatment, and support ongoing monitoring of cancer patients.
FoundationOne®CDx is an FDA-approved qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors that analyzes 324 genes as well as genomic signatures including microsatellite instabi
FoundationOne®Liquid CDx is an FDA-approved qualitative next-generation sequencing based in vitro diagnostic test that analyzes 324 genes utilizing circulating cell-free DNA and reports short variants in 311 genes, rearrangements in 8 genes
Companion diagnostic (CDx) for prescription use to identify patients who may benefit from specific therapies in accordance with approved therapeutic product labeling.
U.S. FDA-approved; approvals issued by the U.S. Food and Drug Administration for companion diagnostic indications.
Foundation Medicine has over 100 FDA-approved companion diagnostic indications in total, with nine FDA-approved companion diagnostic indications for prostate cancer and eight for breast cancer.
Biopharma companies worldwide seeking support across the therapy development lifecycle, from biomarker discovery and trial design to longitudinal molecular monitoring.
HIPAA-compliant handling of protected health information (PHI); maintains a HIPAA Privacy Policy (Notice of Privacy Practices) and requires business associates to appropriately safeguard PHI.
Use of FoundationOne CDx/Liquid CDx does not guarantee a patient will be matched to a treatment; a negative result does not rule out the presence of an alteration; some patients may require a biopsy which may pose a risk.
Official social media presence on LinkedIn, X, YouTube, Facebook, Instagram and BlueSky.
FoundationOne CDx is an FDA-approved tissue-based test that analyzes over 300 genes for all solid tumors
